DMK Pharmaceuticals Corp DMKPQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DMKPQ is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.03
- Day Range
- $0.03–0.04
- 52-Week Range
- $0.02–8.28
- Bid/Ask
- $0.03 / $0.04
- Market Cap
- $302,837.40
- Volume/Avg
- 24,288 / 45,587
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
Valuation
|
Metric
|
DMKPQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.03 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DMKPQ
|
|---|---|
Quick Ratio | — |
Current Ratio | 0.58 |
Interest Coverage | −179.58 |
Quick Ratio
DMKPQ
Profitability
|
Metric
|
DMKPQ
|
|---|---|
Return on Assets (Normalized) | −215.91% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
DMKPQ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Gfmxwbqrhv | Jpmyw | $79.4 Bil | |
MKKGY
| Merck KGaA ADR | Slmtvtthyl | Qxvft | $79.0 Bil | |
HLN
| Haleon PLC ADR | Dzgdbyzb | Htf | $38.5 Bil | |
VTRS
| Viatris Inc | Chpqtthr | Jsgc | $13.1 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mwrpnln | Flzs | $11.7 Bil | |
CTLT
| Catalent Inc | Shrxmfxw | Mxbmgf | $10.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Tzzcywkn | Mpyq | $4.2 Bil | |
PRGO
| Perrigo Co PLC | Dhrrvns | Vckbb | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Jxlhswzd | Xfpvm | $3.2 Bil | |
GTBIF
| Green Thumb Industries Inc | Ljhhtzwwgv | Fwgcv | $3.1 Bil |